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The purpose of this study was to evaluate the effect and
investigate the putative mechanism of botulinum toxin type
A (BTA) applied to the treatment of benign prostatic hyper-
plasia (BPH). A total of 52 patients with symptomatic BPH
were evaluated. Transperineal intraprostatic injection under
transrectal ultrasonography was carried out. BTA dissolved in
4 to 9 mL of saline was used from 100 U to 300 U, ac-
cording to prostate volume. Twenty-six patients received only
BTA (BT group), and 26 received both BTA and one month
of an -adrenergic antagonist (BT group). The therapeutic α α
outcomes were evaluated by comparing parameters such as
international prostate symptom score (IPSS), quality of life,
prostate specific antigen, prostate volume, post-void residual
urine, and peak urinary flow rate. At the one month follow-
up, 18 patients in the BT group and 21 in the BT group had α
subjective symptomatic relief (p = 0.337). Only IPSS5 (weak
stream) was significantly different between the BT group and
BT groups ( α p = 0.034). At the three month follow-up, 39
patients had subjective symptomatic relief. The storage symp-
toms were improved more than the voiding symptoms. Addi-
tionally, about 50 percent of the patients whose voiding
symptom improved expressed improved erectile function.
BTA injection seems to be an alternative treatment for BPH.
The differences after the one month evaluation between the
BT and the BT groups might suggest that the adrenergic α
influence could be relatively reinforced by the anticholinergic
effect of BTA. Nitric oxide would thus be involved in a BTA
action mechanism in BPH.
Key Words: Botulinum toxin type A, benign prostatic
hyperplasia, neurotransmitter
INTRODUCTION
In benign prostatic hyperplasia (BPH), bladder
outlet obstruction is considered to be due to a
mechanical component caused by an enlarged
gland and due to a dynamic component caused by
the tone of prostatic stromal smooth muscle. The
therapeutic goal of BPH has been to perfectly
control both the mechanical and dynamic compo-
nents. Several treatment options have been avail-
able. The treatments include watchful waiting,
pharmacological therapy with an -adrenergic an α -
tagonist and 5 -reductase inhibitor, and surgical α
therapies including simple prostatectomy and
transurethral resection of the prostate (TURP).
Surgery and the 5 -reductase inhibitor have α
played an important role in the treatment of the
mechanical component of BPH. The dynamic
component of BPH is mediated mainly via - α
adrenoceptor stimulation and has been one of the
primary targets for therapeutic interventions with
-adrenergic antagonists. α
1 However, these tradi-
tional methods mainly charge one side between
the mechanical and dynamic components. The tra-
ditional methods also have some adverse conse-
quences. Although TURP has been the less in-
vasive gold standard of treatment against the
mechanical component of BPH, the procedure has
some limitations. Up to 25% of patients who un-
dergo surgery do not have satisfactory long-term
outcomes.
2 TURP also has some troublesome sur-
gical complications. For these reasons, the goal for
patients with BPH is to avoid surgery whenever
possible and to seek a cost-effective alternative
with at an acceptable level of risk for treatment-
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associated complications. While pharmacological
therapies with -adrenergic antago α nists and 5 - α
reductase inhibitors have gained widespread
acceptance as safe and effective treatments for
BPH,
3,4 they have adverse effects such as dizzi-
ness, asthenia, postural hypotension in patients
taking -adrenergic antagonists, and decreased α
libido and impotence in patients taking 5 - α
reductase inhibitors. Medical withdrawal is at-
tributed to these adverse effects. Therefore, a
number of minimally invasive alternatives to
existing traditional treatment options of BPH have
been introduced. The alternatives were devised to
achieve symptomatic improvement without the
surgery-associated morbidity, side effects, or com-
pliance issues associated with medicine.
There has been much interest in botulinum
toxin type A (BTA) as a powerful, versatile tool
because of its safety, effectiveness, specificity, and
reversibility. Urological applications of BTA have
been associated with cases of detrusor external
sphincter dyssynergia, dysfunctional voiding,
detrusor over-activity, and chronic pain syndrome
due to chronic prostatitis. Recent studies have
suggested that BTA is able to be used as an alter-
native treatment for BPH, and it is effective
enough to control both mechanical and dynamic
components of BPH.
5,6 These suggestions are
based on studies which concluded that chemical
denervation using BTA causes subsequent atro-
phy of the gland,
5 that cholinergic stimulation
causes prostatic stromal smooth muscle contrac-
tion,
7 and that BTA blocks acetylcholine release at
the neuromuscular junctions and in autonomic
neurons. We evaluated the effect of BTA in
treating patients with symptomatic BPH and
deduced a putative intraprostatic mechanism of
BTA. The conclusions were drawn from the
analysis of BPH symptoms and the evaluation of
values taken before and after BTA injection into
the prostate.
MATERIALS AND METHODS
This study was approved by the institutional
review board of our hospital and all patients
provided informed consent.
Patients and baseline evaluation
Men between the ages of 45 and 84 years who
had symptomatic BPH volunteered for the study.
All patients were treated with an -adrenergic α
antagonist (42 patients with 4 mg of doxazosin
and 10 with 0.2 mg of tamsulosin) with or without
a 5 reductase inhibitor at least one month before α
this study. They wanted to try a new alternative
to improve BPH related symptoms. All refused
surgical options such as TURP and open prosta-
tectomy.
The inclusion criteria were as follows: urinary
obstruction symptoms as determined by the IPSS
and an enlarged prostate gland on digital rectal
examination. Patients with neurogenic voiding
disorders, prostate or bladder cancer, a serum
PSA level of 15 ng/mL or more, or who had un-
dergone surgery were excluded from the study.
The following evaluations were done at base-
line. The symptoms were assessed with the Inter-
national Prostate Symptom Score (IPSS), which
assesses the occurrence of seven BPH symptoms
and quality of life. Seven BPH symptoms of IPSS
were divided into two groups. One group was
determined to be storage symptoms (IPSS-SS) in-
cluding IPSS 2 (frequency), IPSS 4 (urgency), and
IPSS 7 (nocturia). The other group was deter-
mined to include those with voiding symptoms
(IPSS-VS) including IPSS 1 (incomplete emptying),
IPSS 3 (intermittency), IPSS 5 (weak stream), and
IPSS 6 (straining). Uroflowmetry was performed
to determine peak urinary flow rate. The post-
void residual urinary volume was determined
ultrasonographically. Serum concentrations of
prostate-specific antigen (PSA) were measured.
Transrectal ultrasonography was performed to
determine the prostate volume. Prostate biopsies
were performed if clinically indicated.
Study design
Eligible applicants were enrolled from April
2004 to January 2005. Patients were divided into
two groups under our hypothesis that BTA could
induce change in neural balancing among
adrenergic, cholinergic, and nonadrenergic-non-
cholinergic (NANC) nerves in the prostate. We
also hypothesized that a decreased cholinergicDong Soo Park, et al.
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neural effect by BTA could increase adrenergic
nerve activity after BTA application. This disrup-
tion of neural balancing would be modified by
slowly increasing NANC neural activity, which is
related with nitric oxide production. Under these
hypotheses, one group received BPH related
medical treatment of an -adrenergic antagonist α
(Doxazosin, 4 mg) for one month just after BTA
injection. The other group did not receive medical
treatment after BTA injection. The study was de-
signed to continue for at least 3 months. Randomi-
zation was performed after informed consent was
obtained. The randomization data was available
only to the doctors who performed medical treat-
ment. The data was not available to the investi-
gators who were in charge of the procedures of
BTA injection and evaluation methods.
Each of the participants received BTA (Botox ),
Allergan) dissolved in 4 to 9 mL of 0.9% sodium
chloride solution via injection into the prostate.
The BTA was divided into two equal injections
into each transition zone of the gland. However,
BTA was only injected into the bilateral lobe in
the case of a small prostate. With the patient lying
on the lithotomy position, a transperineal intra-
prostatic injection was carried-out using a 22-
gauge, 15-cm spinal needle. Transrectal ultrasono-
graphy was performed for appropriate localiza-
tion of the injection site and confirmation of BTA
diffusion. Neither sedation nor local anesthesia
was used during the procedure. BTA from 100 to
300 U was given to each patient according to the
prostate volume (below 30 mL, 100 U; 30 mL to 80
mL, 200 U; above 80 mL, 300 U). One hundred U,
200 U, and 300 U of BTA were dissolved in 4 mL,
6 mL, and 9 mL of normal saline, respectively.
A follow-up of the patients was done to evalu-
ate their outcome at 1, 3, and 6 months. Regard-
less of their treatment and outcome, all patients
underwent the same evaluation as performed at
baseline. Evaluation of symptomatic improvement
after treatment, as measured by the IPSS, peak
urinary flow rates, postvoid residual urinary vol-
ume, evaluation of prostate volume, and serum
PSA level, was performed. If patients complained
that BTA had little effect and did not want to stay
in the study, they were offered medical therapy or
surgical resection at each follow-up visit.
Statistical analysis
All statistical analyses were obtained using the
Statistical Package for the Social Science (SPSS,
version 13.0, Chicago, IL, USA ) for Windows. The
results are expressed as the mean ± standard devi-
ation. Differences between data were compared
using the Student t-test. The clinical outcomes of
the two groups were compared using the Pearson
Chi Square test. All p values were two tailed. A p
< 0.05 was considered statistically significant.
RESULTS
Fifty-two outpatients were selected after confir-
mation of eligibility according to the inclusion
criteria and were randomized. Among these
patients, 10 were biopsy-proven benign condi-
tions. A biopsy was performed if the serum PSA
level was more than 4.0 ng/mL and/or a palpable
nodule was present in the prostate. Twenty-six
received only BT (BT group), and 26 received both
BT and one month of an -adrenergic antagonist α
(BT group). A follow-up of 52 patients was done α
at one month and three months. At the six-month
follow-up, 23 patients between the ages of 54 to
81 years stayed in the study and underwent the
same evaluations as performed at baseline, except
PSA. No complications during the procedure were
observed in any patient. Urinary incontinence,
urinary retention, and adverse events of BTA
enough to stop the study were not reported
during the follow-up period.
One-month evaluation
Eighteen patients in the BT group and 21 in the
BT group had subjective symptomatic relief with α
23.8 percent and 27.8 percent reduction of IPSS,
respectively (p = 0.337). No differences were found
at baseline between the two groups or between
the BT group and the total (52 patients) group
(Table 1). In the BT patients, IPSS including the
total IPSS score and 6 BPH symptoms (except IPSS
5), quality of life and prostate volume were sig-
nificantly reduced compared with baseline values,
by 23.8%, 25.8% and 8.1% for total IPSS score,
quality of life and prostate volume, respectively.Botulinum Toxin Type A in Prostate
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PSA and postvoid residual volume were reduced
by 9.0% and 24.0%. Peak urinary flow rate was
increased by 11.1%, while IPSS 5, PSA, peak uri-
nary flow rate, and postvoid residual volume
were not significantly different from baseline.
IPSS-SS was reduced more than IPSS-VS (IPSS-
SS, 30.0%; IPSS-VS, 19.3%). The number of im-
proved patients was not significantly different
between IPSS-SS (12/26) and IPSS-VS (18/26) (p=
0.092).
In the BT patients, compared with baseline α
values, total IPSS (and all IPSS symptoms),
quality of life and prostate volume were signifi-
cantly reduced by 27.8%, 33.1% and 9.0%, respec-
tively. PSA and postvoid residual volume were
reduced by 8.7% and 30.5%, respectively. Peak
urinary flow rate was increased by 12.0%,
though this difference was not statistically signi-
ficant. IPSS-SS was reduced less than IPSS-VS
(IPSS-SS, 27.5%; IPSS-VS, 28.1%). The number of
improved patients was not significantly different
between IPSS-SS (19/26) and IPSS-VS (21/26) (p=
0.510). Only IPSS5 was significantly different
between the BT group and the BT groups ( α p =
0.034). IPSS5 showed weaker improvement after
BTA injection in the BT group (Fig. 1). This
means that the -adrenergic α antagonist might
improve the urine stream in BTA treated condi-
tions.
Table 1. Evaluation Results at Baseline and One-month Follow-up
BT group BT group α
Characteristic Baseline 1 month Baseline 1 month
Patients (n) 26 26
Age (yr) 65 ± 10.4 67.8 ± 6.1
Total IPSS score 24.2 ± 8.7* 18.5 ± 8.2* 24.3 ± 6.8 17.5 ± 7.2
IPSS-SS 10.3 ± 3.6 7.2 ± 3.6 10.5 ± 3.5 7.6 ± 3.2
IPSS-VS 14.0 ± 5.3 11.3 ± 5.2 13.8 ± 4.1 9.9 ± 4.8
Quality of life 4.6 ± 0.9 3.4 ± 1.3 5.0 ± 0.7 3.3 ± 1.4
PSA (ng/mL) 2.6 ± 3.2 2.4 ± 3.1 2.4 ± 1.8 2.2 ± 1.3
Prostate volume (mL) 47.9 ± 27.8 44.1 ± 25.3 46.6 ± 19.3
§ 42.4 ± 15.0
§
Peak urinary flow rate (mL/s) 9.1 ± 5.9 10.1 ± 5.6 10.2 ± 7.0 11.4 ± 6.3
Residual urinary volume (mL) 108.1 ± 129.6 82.2 ± 63.6 137.4 ± 150.4 95.5 ± 68.1
BT, Botulinum toxin A; BT , botulinum toxin A plus a-adrenergic antagonist; PSA, prostate specific antigen; IPSS-SS, Interna α tional
prostate symptom score-storage symptom; IPSS-VS, International prostate symptom score-voiding symptom.
Data presented as the mean ± SD.
*p = 0.001, p < 0.001, p < 0.001,
§p = 0.009.
Fig. 1. IPSS 5 changes between two groups after one
month botulinum toxin A administration. p = 0.034; BT,
Botulinum toxin A injection; BT , botulinum toxin A plus α
a-adrenergic antagonist; IPSS, International prostate
symptom score.Dong Soo Park, et al.
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Three-month evaluation
Thirty-nine patients had subjective symptomatic
relief. The number of improved patients was not
significantly different compared with the one-
month BT group and the six-month follow-up
group (p = 0.077). IPSS, quality of life, prostate
volume, peak urinary flow rate, and postvoid
residual volume were significantly different com-
pared with baseline values of the total (52 patients)
group. IPSS, quality of life, prostate volume, and
residual urine were reduced by 30.3%, 34.4%,
13.1%, and 34.3%, respectively. Peak urinary flow
rate was increased by 15.5% (Table 2).
IPSS-SS was not significantly different between
the one-month BT group (12/26) and the three-
month follow-up group (45/52) (p = 0.293). IPSS-
VS was not significantly different between the BT
group of the one-month follow-up (18/26) and
three-month follow-up groups (38/52) (p = 0.722).
However, both the IPSS-SS and IPSS-VS were
improved more than those of the BT group at the
one-month follow-up. IPSS-SS was still reduced
more than IPSS-VS (IPSS-SS, 39.1%; IPSS-VS,
23.8%).
Compared with the BT group at one-month
follow-up, IPSS (except IPSS 2), quality of life,
prostate volume, peak urinary flow rate, and
residual urine were not significantly different.
Only IPSS2 was significantly different (p = 0.039)
(Fig. 2). PSA was not checked at the three-month
follow-up.
Six-month evaluation
Twenty-one patients had subjective sympto-
matic relief. IPSS, quality of life, prostate volume,
peak urinary flow rate, and postvoid residual
volume of the six-month follow-up group were
significantly different compared with the baseline
values. IPSS, quality of life, prostate volume, and
Table 2. Evaluation Results at Three and Six-months Follow-up
Characteristic Baseline 3 months Baseline 6 months
Patients (n) 52 23
Age (yr) 66.7 ± 8.6 66.3 ± 7.5
Total IPSS score 24.3 ± 7.8 16.9 ± 6.4 24.0 ± 8.3 14.7 ± 6.0
IPSS-SS 10.4 ± 3.6 9.0 ± 3.9 12.9 ± 5.3 7.7 ± 3.9
IPSS-VS 13.9 ± 4.8 7.9 ± 3.4 11.1 ± 3.5 7.0 ± 3.0
Quality of life 4.8 ± 0.9 3.2 ± 1.2 4.7 ± 1.0 3.0 ± 0.8
Prostate volume (mL) 47.2 ± 23.9 41.0 ± 19.0 47.5 ± 26.4 40.8 ± 19.1
Peak urinary flow rate (mL/s) 9.6 ± 6.5 11.1 ± 5.9 7.4 ± 3.6 9.4 ± 3.1
Residual urinary volume (mL) 122.7 ± 141.2 80.7 ± 40.9 108.7 ± 126.7 59.4 ± 33.4
IPSS-SS, International prostate symptom score-storage symptom; IPSS-VS, International prostate symptom score-voiding symptom.
Fig. 2. IPSS 2 changes between one month and three
months after botulinum toxin A administration. p = 0.039;
IPSS, International prostate symptom score. BT, botulinum
toxin.Botulinum Toxin Type A in Prostate
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postvoid residual volume were reduced by 38.8%,
35.5%, 14.2%, and 45.3%, respectively. Peak uri-
nary flow rate was increased by 27.6%.
The number of patients who were improved in
IPSS was significantly different between the BT
group (12/26) of the one-month follow-up and the
six month follow-up groups (21/23) (p= 0.015) (Fig.
3). The number of patients who were improved in
IPSS-VS was not significantly different between the
BT group of the one-month follow-up (18/26) and
the three-month follow-up group (21/23) (p =
0.056). However, both IPSS-SS and IPSS-VS were
improved more than those of the BT group of the
one-month follow-up and the three-month follow-
up groups. IPSS-SS was still reduced more than
IPSS-VS (IPSS-SS, 39.4%; IPSS-VS, 38.5%).
No differences were found between the total (52
patients) group at baseline and the six-month fol-
low-up. Compared with the three-month follow-
up values, IPSS, quality of life, prostate volume,
peak urinary flow rate, and residual urine were
not significantly different.
DISCUSSION
Neural activity has been thought to be involved
in normal growth and functioning of the prostate.
8
Dysregulation of this neuronal activity may alter
the morphology and behavior of the prostate.
These pathological events are caused by signifi-
cant alteration of neurotransmitter/growth factor
influence on the prostate and may result in BPH.
Therefore, normalization or favorable correction of
altered neural activity could significantly reverse
pathological processes and improve stressful BPH
related symptoms.
The prostate is a heterogeneous tissue com-
posed of epithelial cells, smooth muscle cells,
fibroblasts, and connective tissue element. Bartsch
and colleagues, using quantitative morphometry,
demonstrated that the ratio of stroma to epithe-
lium in the normal prostate is two to one. Bartsch
also demonstrated that benign prostatic hyper-
plasia is primarily a stromal process, as the ratio
of stroma to epithelium is five to one.
9 Fibromu-
scular stroma, especially smooth muscle element,
which has the principal to cause and aggravate
BPH symptoms, has been the primary target for
BPH therapy. Human prostate contains -1 α
adrenergic, cholinergic, and non-adrenergic non-
cholinergic (NANC) neuroreceptors under the in-
fluence of various differentiated autonomous in-
nervation.
10-12 It is widely believed that the pro-
static epithelium receives a cholinergic innerva-
tion while the stroma receives a predominantly
noradrenergic innervation. The fact has been
known that nerve fibers innervating the smooth
muscle may be both noradrenergic and choliner-
gic or separate. The fibers can cause an increase
of smooth muscle tone.
13 Nitric oxide (NO) plays
an important role in relaxation of the prostate
smooth muscle.
14 Additionally, It has been sug-
gested that cholinergic nerves in the prostatic
stroma could suppress the release of noradrena-
line from adrenergic terminals.
15 The -adrenergic α
innervation may be antagonized by NANC-in-
duced relaxation mediated by NO.
16,17 The adren-
ergic, cholinergic, and nitrinergic innervations and
their interaction may be related with prostate
smooth muscle tone. Thus, they may play an im-
portant role in the dynamic component of benign
prostatic hyperplasia. The cholinergic and nitrin-
ergic innervation are reduced in BPH as compared
to that in normal prostate tissue. However, ad-
renergic activity is increased.
16
Recent studies have suggested that BTA is able
to be a prominent medical tool for BPH. BTA acts
Fig. 3. IPSS changes between one month and six months
after botulinum toxin A administration. p = 0.015; IPSS,
International prostate symptom score. BT, botulinum toxin.Dong Soo Park, et al.
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as a favorable controller of various neural acti-
vities that innervate the prostate. BTA has been
known to reduce peripheral sensitization by inhi-
biting the release of acetylcholine at the presy-
naptic cholinergic junction. Though BTA exhibits
prevalent cholinergic specificity in its action on
nerve terminals, release of many neurotrans-
mitters can be blocked when adequate concen-
trations of toxin are used.
18
In our study, only subjective values like IPSS
were improved. Objective values such as peak
urinary flow rate and postvoid residual volume
were not improved at the one-month follow-up.
Most patients reported improvement of subjective
values starting approximately one to three weeks,
if improved. Improvement of objective values
started after one month, reached a plateau within
three months, and lasted for six months. IPSS 4,
IPSS 6, and residual urine were more improved
than other values. IPSS-SS improved more than
IPSS-VS. On the contrary, the BT group patients
complained of little effect of BTA on weak stream.
IPSS 5, PSA, peak urinary flow rate, and pos-
tvoid residual volume were not significantly
different in the BT patients at one-month follow-
up compared with baseline values. IPSS (except
IPSS 5), quality of life, PSA, prostate volume, peak
urinary flow rate, and postvoid residual volume
urine were not significantly different between the
BT and BT groups at one-month follow-up. α
These facts mean that adrenergic nerve terminals
were not affected by BTA. BTA has been sug-
gested to be able to affect other neurotransmitters.
If they were affected, peak urinary flow rate and
postvoid residual volume should be improved in
the BT patients. Additionally, the reinforcement of
adrenergic activity may develop. These results
could easily be deduced from the fact that little
difference was found between the BT and BTα
groups at the one-month follow-up. This means
that the combined -adrenergic antagonist in the α
BT group did little work. Loss of acetylcholine- α
mediated suppression of adrenergic transmission
from adrenergic terminals in the prostate may be
one of the various putative BTA mechanisms to
increase smooth muscle tone.
Prostate volume was reduced compared with
baseline values at the one-month follow-up, but
the change of prostate volume did not alter the
PSA level to a lower level. Prostate volume was
reduced only by 14.2% at the six-month follow-up.
This is thought to result from the fact that BTA
might induce atrophy and apoptosis of glandular
epithelium. There was lesser effect on the stromal
component of the transition zone, while the stro-
mal component is dominant in BPH. However,
pathological confirmation was not performed. It is
easy to presume these findings from the fact that
the rat prostate used in a recent study showed
profound atrophy of the prostate gland which was
mainly glandular.
7 Also, BPH in human is pri-
marily a stromal process as previously described.
Peak urinary flow rate was increased by 15.5%
and 27.6% at the three and six-months follow-up,
respectively. Residual urine was reduced by 34.3%
and 45.3% at the three and six-months follow-up,
respectively. This may result from the improve-
ment of the mechanical component of BPH by
glandular atrophy. It may also result from an
improvement of the dynamic component by a
disclosed effect of BTA related with the inhibition
of acetylcholine release on the smooth muscle
tone. The improvement of the dynamic com-
ponent may be hidden at the one-month follow-
up because of the transient contraction effect by
stronger adrenergic activity. This may mask the
relaxation effect of smooth muscle by inhibition of
acetylcholine release by BTA. The good results in
the parameters of the IPSS score and residual
urine in patients at the six-months follow-up may
be influenced by reduced objectives. Therefore,
this study needs to be placebo-controlled in the
future.
We found two interesting NO related events
which were not expected in the study, and that it
can induce an additional putative BTA mecha-
nism. It has been reported that an NO donor, such
as isosorbide dinitrate or glyceryl trinitrate medi-
cation, in ischemic heart disease patients improves
micturition parameters in symptomatic BPH
patients.
19 Five patients who took oral isosorbide
dinitrate for an ischemic heart disease and per-
sisted stressful BPH symptoms received BTA
injection. All patients showed no improvement of
BPH related evaluation values during the follow-
up period. Another unexpected effect was the
improvement of erectile function. Nearly half of
the improved patients (19/39; data not shown) atBotulinum Toxin Type A in Prostate
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the three-month follow-up showed an improve-
ment of erectile frequency [International Index of
Erection Function (IIEF)]. This is likely caused by
the diffusion of BTA to the adjacent nerve plexus
outside the prostate. The prostate is surrounded
by a dense nerve plexus derived from both hypo-
gastric and pelvic nerves. These nerves project to
other regions of the male genital tract including
the corpus cavernosum. Acetylcholinesterase reac-
tivity has been reported to be closely related to
NO synthase immunoreactivity in the prostate.
20
This suggests that there may be functional interac-
tions between NO and acetylcholine in the pros-
tate. Based on these facts, an additional mech-
anism of BTA, one that nitrinergic activity in the
prostate is increased under inhibition of acetyl-
choline release by BTA, could be derived from the
improvement of erectile dysfunction. The im-
provement of erectile function may be caused by
accessory nerve sprouting or increased release of
NO at the nitrinergic nerve endings.
21 This in-
creased nitrinergic activity does not occur when
NO is sufficiently supplied to the prostate by oral
nitrate.
In our study, there are several shortcomings of
the baseline evaluation and study model. Firstly,
the patients did not undergo urodynamic study at
baseline evaluation. A second shortcoming was
the lack of a placebo. These made it difficult to
assess the true efficacy of BTA. Although a level
of caution must be present in interpreting the
results of the study, we believe that they may be
a kind of guideline for more profound, genera-
lized studies on the combination effect of BTA
and existing BPH medicines.
In summary, we were able to deduce the intra-
prostatic mechanism of BTA from the difference
between various evaluation values related to BPH
before and after BTA injection. It is mainly related
with the alteration of interactions between adren-
ergic, cholinergic, and nitrinergic activity. How-
ever, it is possible that more neurotransmitters
than the three neurotransmitters mentioned are
involved in making BPH. Additional histopatho-
logic and pharmacophysiological investigations of
BTA treatment are necessary before the effects of
BTA seen in our results can be generalized in BPH
treatment.
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